Novo Nordisk A/S (CO:NOVO-B) — Stock Price

Dkr306.15 DKK
▲ 0.34% today

Novo Nordisk A/S (CO:NOVO-B) is currently trading at Dkr306.15 DKK, up 0.34% today. Over the past 52 weeks, shares have ranged between Dkr228.50 and Dkr401.35. This page tracks Novo Nordisk A/S's live share price on the CO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see how much is Novo Nordisk A/S worth.

Novo Nordisk A/S (NOVO-B) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Novo Nordisk A/S's daily closing share price and trading volume on the CO exchange over the past year, giving a clear view of recent price momentum and liquidity.

Novo Nordisk A/S Income Statement — Revenue, Profit & Earnings by Year

Novo Nordisk A/S's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20252024202320222021
Total Revenue Dkr309.06 Billion Dkr290.40 Billion Dkr232.26 Billion Dkr176.95 Billion Dkr140.80 Billion
Cost of Revenue Dkr60.76 Billion Dkr44.52 Billion Dkr35.77 Billion Dkr28.45 Billion Dkr23.66 Billion
Gross Profit Dkr248.31 Billion Dkr245.88 Billion Dkr196.50 Billion Dkr148.51 Billion Dkr117.14 Billion
Research & Development Dkr45.22 Billion Dkr48.06 Billion Dkr32.44 Billion Dkr24.05 Billion Dkr17.77 Billion
SG&A Dkr70.28 Billion Dkr5.28 Billion Dkr61.60 Billion Dkr4.47 Billion Dkr4.05 Billion
Total Operating Expenses Dkr113.29 Billion Dkr117.54 Billion Dkr129.69 Billion Dkr73.70 Billion Dkr58.50 Billion
Operating Income Dkr135.02 Billion Dkr128.34 Billion Dkr102.57 Billion Dkr74.81 Billion Dkr58.64 Billion
EBITDA Dkr149.44 Billion Dkr137.38 Billion Dkr112.94 Billion Dkr82.04 Billion Dkr67.56 Billion
EBIT Dkr134.77 Billion Dkr128.83 Billion Dkr102.57 Billion Dkr74.81 Billion Dkr58.64 Billion
Interest Expense Dkr6.78 Billion Dkr1.93 Billion Dkr542.00 Million Dkr378.00 Million Dkr2.45 Billion
Income Before Tax Dkr130.54 Billion Dkr127.19 Billion Dkr104.67 Billion Dkr69.06 Billion Dkr59.08 Billion
Income Tax Expense Dkr28.11 Billion Dkr26.20 Billion Dkr20.99 Billion Dkr13.54 Billion Dkr11.32 Billion
Net Income Dkr102.43 Billion Dkr100.99 Billion Dkr83.68 Billion Dkr55.52 Billion Dkr47.76 Billion

Novo Nordisk A/S Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Novo Nordisk A/S's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20252024202320222021
Total Assets Dkr542.90 Billion Dkr465.80 Billion Dkr314.49 Billion Dkr241.26 Billion Dkr194.51 Billion
Total Current Assets Dkr172.45 Billion Dkr160.90 Billion Dkr139.65 Billion Dkr108.19 Billion Dkr85.59 Billion
Cash & Equivalents — — — Dkr12.65 Billion Dkr10.72 Billion
Short-term Investments Dkr498.00 Million Dkr10.65 Billion Dkr15.84 Billion Dkr10.92 Billion Dkr6.76 Billion
Net Receivables Dkr75.70 Billion Dkr87.41 Billion Dkr64.77 Billion Dkr57.51 Billion Dkr46.80 Billion
Inventory Dkr49.62 Billion Dkr40.85 Billion Dkr31.81 Billion Dkr24.39 Billion Dkr19.62 Billion
Property, Plant & Equipment — — — Dkr66.67 Billion Dkr55.36 Billion
Goodwill Dkr19.84 Billion Dkr20.06 Billion Dkr4.46 Billion Dkr5.09 Billion Dkr4.35 Billion
Total Liabilities Dkr348.86 Billion Dkr322.31 Billion Dkr207.93 Billion Dkr157.77 Billion Dkr123.76 Billion
Total Current Liabilities Dkr215.66 Billion Dkr217.53 Billion Dkr169.66 Billion Dkr120.94 Billion Dkr99.52 Billion
Long-term Debt Dkr111.70 Billion Dkr84.25 Billion Dkr15.98 Billion Dkr20.77 Billion Dkr9.65 Billion
Net Debt Dkr104.49 Billion Dkr87.13 Billion Dkr6.89 Billion Dkr13.13 Billion Dkr15.93 Billion
Total Stockholder Equity Dkr194.05 Billion Dkr143.49 Billion Dkr106.56 Billion Dkr83.49 Billion Dkr70.75 Billion
Retained Earnings Dkr195.30 Billion Dkr144.45 Billion Dkr104.84 Billion Dkr80.59 Billion Dkr72.00 Billion

Novo Nordisk A/S Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Novo Nordisk A/S generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20252024202320222021
Operating Cash Flow Dkr119.10 Billion Dkr120.97 Billion Dkr108.91 Billion Dkr78.89 Billion Dkr55.00 Billion
Capital Expenditures Dkr60.14 Billion Dkr51.31 Billion Dkr38.90 Billion Dkr14.75 Billion Dkr7.38 Billion
Free Cash Flow Dkr58.96 Billion Dkr69.66 Billion Dkr70.01 Billion Dkr64.13 Billion Dkr47.62 Billion
Investing Cash Flow Dkr-79.16 Billion Dkr-128.90 Billion Dkr-43.89 Billion Dkr-24.92 Billion Dkr-31.61 Billion
Financing Cash Flow Dkr-28.41 Billion Dkr8.73 Billion Dkr-63.16 Billion Dkr-51.80 Billion Dkr-25.49 Billion
Dividends Paid Dkr51.76 Billion Dkr44.14 Billion Dkr31.77 Billion Dkr25.30 Billion Dkr21.52 Billion
Stock-Based Compensation — Dkr2.29 Billion Dkr2.15 Billion Dkr1.54 Billion Dkr1.04 Billion
Depreciation Dkr21.98 Billion Dkr8.54 Billion Dkr9.41 Billion Dkr7.36 Billion Dkr6.03 Billion
Change in Cash Dkr10.81 Billion Dkr1.26 Billion Dkr1.74 Billion Dkr1.93 Billion Dkr-1.51 Billion

Novo Nordisk A/S Earnings History — EPS Actual vs. Analyst Estimates

Track Novo Nordisk A/S's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
May 06, 2026 — 5.18 —
Feb 03, 2026 6.04 5.78 +4.50%
Nov 05, 2025 4.50 4.90 -8.16%
Aug 06, 2025 5.96 6.07 -1.81%
May 07, 2025 6.53 6.11 +6.87%
Feb 04, 2025 6.34 5.88 +7.82%
Nov 06, 2024 6.12 6.01 +1.83%
Aug 07, 2024 4.49 4.97 -9.66%